If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Nausea and Vomiting Related to Cancer Treatment (PDQ®)–Health Professional Version was originally published by the National Cancer Institute.”
Steroids can help to control sickness. They can help particularly with sickness from:
Steroids reduce swelling so they can help to lower pressure in the skull, which causes sickness. They might reduce swelling around a tumour blocking the gut and help to allow fluids to pass through. This relieves the vomiting that a bowel obstruction can cause. Steroids will only work for a limited time. But they might help until you have other treatment. Or, they can help to make you more comfortable. Dexamethasone is a steroid that you could have as an injection into a vein just before chemotherapy. You might have steroid tablets to take at home for a couple of days after chemotherapy. Dexamethasone can cause difficulty with sleeping and so it’s better if you take it before lunchtime. 1. Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol. 2007;61(2):162–175. [PubMed] [Google Scholar] 2. Doherty KM. Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs. 1999;3(3):113–119. [PubMed] [Google Scholar] 3. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J. 2008;14(2):85–93. [PubMed] [Google Scholar] 4. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482–2494. [PubMed] [Google Scholar] 5. Warr DG, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer. 2011;19(6):807–813. [PubMed] [Google Scholar] 6. Hesketh PJ, Aapro M, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. 2010;18(9):1171–1177. [PubMed] [Google Scholar] 7. Vardy J CK, Galica J, et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer. 2006;94:1011–1015. [PMC free article] [PubMed] [Google Scholar] 8. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 20. 2006;24(18):2932–2947. [PubMed] [Google Scholar] 9. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol. 2006;17(1):20–28. [PubMed] [Google Scholar] 10. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23(6):1289–1294. [PubMed] [Google Scholar] 11. Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother. 2003;37(9):1276–1286. [PubMed] [Google Scholar] 12. NCCN Clinical practice guidelines in oncology; v1.2012: Antiemesis National Comprehensive Cancer Network (NCC)2012Available from: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdfAccessed August 4, 2011 [Google Scholar] 13. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999;17(9):2971–2994. [PubMed] [Google Scholar] 14. Kris MG, Hesketh PJ, Herrstedt J, et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer. 2005;13(2):85–96. [PubMed] [Google Scholar] 15. Herrstedt J, Koeller JM, Roila F, et al. Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer. 2005;13(2):97–103. [PubMed] [Google Scholar] 16. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. The Italian Group for Antiemetic Research. N Engl J Med. 1995;5332(1):1–5. [PubMed] [Google Scholar] 17. Carmichael J, Bessell EM, Harris AL, et al. Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis. Br J Cancer. 1994;70(6):1161–1164. [PMC free article] [PubMed] [Google Scholar] 18. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 1991;9(4):675–678. [PubMed] [Google Scholar] 19. Latreille J, Stewart D, Laberge F, et al. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy. Support Care Cancer. 1995;3(5):307–312. [PubMed] [Google Scholar] 20. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98(11):2473–2482. [PubMed] [Google Scholar] 21. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14(10):1570–1577. [PubMed] [Google Scholar] 22. Navari RM. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol. 2006;2(5):591–602. [PubMed] [Google Scholar] 23. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10(2):115–124. [PubMed] [Google Scholar] 24. Aapro M, Fabi A, Nole F, et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol. 2010;21(5):1083–1088. [PubMed] [Google Scholar] 25. Celio L, Frustaci S, Denaro A, et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer. 2011;19(8):1217–1225. [PMC free article] [PubMed] [Google Scholar] 26. Grunberg S DV, Zufferli M, Piraccini G. Oral palonosetron is as effective as intravenous palonosetron: a Phase 3 dose ranging trial in patients receiving moderately emetogenic chemotherapy; 14th European Conference of Clinical Oncology, oral poster; 2007. [Google Scholar] 27. ECCO Oral palonosetron is as effective as intravenous palonosetron: a Phase 3 dose ranging trial in patients receiving moderately emetogenic chemotherapy; 14th European Conference of Clinical Oncology, oral poster; 2007. [Google Scholar] 28. Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E, Pegoretti B. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer. 2011;19(6):823–832. [PubMed] [Google Scholar] 29. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21(22):4112–4119. [PubMed] [Google Scholar] 30. Navari RM, Province PS. Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006;11(1):137–151. [PubMed] [Google Scholar] 31. Bountra C BK, Dale T, et al. Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagnoist, CP-99, 994. Eur J Pharmacol. 1993;249:R3–R4. [PubMed] [Google Scholar] 32. Gralla RJ, de Wit R, Herrstedt J, et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer. 2005;104(4):864–868. [PubMed] [Google Scholar] 33. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23(12):2822–2830. [PubMed] [Google Scholar] 34. Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005;104(7):1548–1555. [PubMed] [Google Scholar] 35. Yeo W, Mo FK, Suen JJ, et al. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat. 2009;113(3):529–535. [PubMed] [Google Scholar] 36. Grunberg SM, Dugan M, Muss H, et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer. 2009;17(5):589–594. [PubMed] [Google Scholar] 37. Navari RM. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs. 2007;16(12):1977–1985. [PubMed] [Google Scholar] 38. Cocquyt V, Van Belle S, Reinhardt RR, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer. 2001;37(7):835–842. [PubMed] [Google Scholar] 39. Van Belle S LM, Navari RM, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 anatgonists, L-758,298 and MK-869. Cancer. 2002;94:3032–3041. [PubMed] [Google Scholar] 40. Herrstedt J, Apornwirat W, Shaharyar A, et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol. 2009;27(32):5363–5369. [PubMed] [Google Scholar] 41. Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol – EASE. J Clin Oncol. 2011;29(11):1495–1501. [PubMed] [Google Scholar] 42. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97(12):3090–3098. [PubMed] [Google Scholar] 43. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17(6):1000–1006. [PubMed] [Google Scholar] 44. Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer. 2005;41(9):1278–1285. [PubMed] [Google Scholar] 45. Shadle CR, Lee Y, Majumdar AK, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol. 2004;44(3):215–223. [PubMed] [Google Scholar] 46. Massaro AM, Lenz KL. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother. 2005;39(1):77–85. [PubMed] [Google Scholar] 47. McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74(1):17–24. [PubMed] [Google Scholar] 48. Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2004;64(7):777–794. [PubMed] [Google Scholar] 49. Depre M, Van Hecken A, Oeyen M, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol. 2005;61(5–6):341–346. [PubMed] [Google Scholar] 50. Aapro MS, Walko CM. Aprepitant: drug-drug interactions in perspective. Ann Oncol. 2010;21(12):2316–2323. [PubMed] [Google Scholar] 51. Nygren P, Hande K, Petty KJ, et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol. 2005 Jun;55(6):609–616. [PubMed] [Google Scholar] 52. de Jonge ME, Huitema AD, Holtkamp MJ, van Dam SM, Beijnen JH, Rodenhuis S. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol. 2005;56(4):370–378. [PubMed] [Google Scholar] 53. Reddy BY, Trzaska KA, Murthy RG, Navarro P, Rameshwar P. Neurokinin receptors as potential targets in breast cancer treatment. Curr Drug Discov Technol. 2008;5(1):15–19. [PubMed] [Google Scholar] 54. Vermeulen LC, Jr, Matuszewski KA, Ratko TA, Butler CD, Burnett DA, Vlasses PH. Evaluation of ondansetron prescribing in US academic medical centers. Arch Intern Med. 1994;154(15):1733–1740. [PubMed] [Google Scholar] 55. Fabi A, Barduagni M, Lauro S, et al. Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer. 2003;11(3):156–161. [PubMed] [Google Scholar] 56. Antiemetic prescription in Italian breast cancer patients submitted to adjuvant chemotherapy. Support Care Cancer. 2003;11(12):785–789. [PubMed] [Google Scholar] 57. Kaiser R. Antiemetic guidelines: are they being used? Lancet Oncol. 2005;6(8):622–625. [PubMed] [Google Scholar] 58. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(Suppl 5):v232–v243. [PubMed] [Google Scholar] Page 2Relative emetogenic potential of chemotherapeutic agents in breast cancer patients (if no antiemetic prophylaxis is used)a
|
What is the best antiemetic for chemotherapy?
Postagens relacionadas
direito autoral © 2024 aprendervalor Inc.
